These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11534539)

  • 21. Lifetime antipsychotic-drug exposure, dyskinesia and related movement disorders in the developmentally disabled.
    Stone RK; Alvarez WF; Ellman G
    Pharmacol Biochem Behav; 1989 Dec; 34(4):759-63. PubMed ID: 2576142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tardive dyskinesia in young mentally retarded individuals.
    Gualtieri CT; Schroeder SR; Hicks RE; Quade D
    Arch Gen Psychiatry; 1986 Apr; 43(4):335-40. PubMed ID: 2869741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities.
    Matson JL; Mayville EA; Bielecki J; Smalls Y; Eckholdt CS
    Res Dev Disabil; 2002; 23(3):224-33. PubMed ID: 12102590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia in the aged. Duration of treatment relationships.
    Toenniessen LM; Casey DE; McFarland BH
    Arch Gen Psychiatry; 1985 Mar; 42(3):278-84. PubMed ID: 2858189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents.
    Gualtieri CT; Quade D; Hicks RE; Mayo JP; Schroeder SR
    Am J Psychiatry; 1984 Jan; 141(1):20-3. PubMed ID: 6140865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors in the development of severe forms of tardive dyskinesia.
    Yassa R; Nair NP; Iskander H; Schwartz G
    Am J Psychiatry; 1990 Sep; 147(9):1156-63. PubMed ID: 1974745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of tardive dyskinesia among psychiatric in-patients at Mathari Hospital, Nairobi.
    Gatere N; Othieno CJ; Kathuku DM
    East Afr Med J; 2002 Oct; 79(10):547-9. PubMed ID: 12635762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological determinants and risk factors for tardive dyskinesia in schizophrenia.
    Sandyk R
    Int J Neurosci; 1993; 69(1-4):35-51. PubMed ID: 7916008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population.
    Morgenstern H; Glazer WM; Gibowski LD; Holmberg S
    J Chronic Dis; 1987; 40(4):319-27. PubMed ID: 2881941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of tardive dyskinesia.
    Tepper SJ; Haas JF
    J Clin Psychiatry; 1979 Dec; 40(12):508-16. PubMed ID: 40964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use.
    Matson JL; Fodstad JC; Neal D; Dempsey T; Rivet TT
    Res Dev Disabil; 2010; 31(1):108-16. PubMed ID: 19720497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal.
    Newell KM; Wszola B; Sprague RL; Mahorney SL; Bodfish JW
    Exp Clin Psychopharmacol; 2001 Aug; 9(3):262-8. PubMed ID: 11534536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM; Morgenstern H; Doucette JT
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes and development of tardive dyskinesia.
    Woerner MG; Saltz BL; Kane JM; Lieberman JA; Alvir JM
    Am J Psychiatry; 1993 Jun; 150(6):966-8. PubMed ID: 8098587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.
    Jeste DV; Lacro JP; Palmer B; Rockwell E; Harris MJ; Caligiuri MP
    Am J Psychiatry; 1999 Feb; 156(2):309-11. PubMed ID: 9989570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
    Bailey LG; Maxwell S; Brandabur MM
    Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tardive dyskinesia and atypical antipsychotic drugs.
    Casey DE
    Schizophr Res; 1999 Mar; 35 Suppl():S61-6. PubMed ID: 10190226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia.
    Lerner V; Miodownik C; Kaptsan A; Vishne T; Sela BA; Levine J
    J Clin Psychiatry; 2005 Dec; 66(12):1558-63. PubMed ID: 16401157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.